Residual Host Cell DNA Analysis: Ensure the Purity and Compliance of Your Biotherapeutics
Master Genomic Impurities to Secure the Market Launch of Your Biological Products
In the production of recombinant proteins, of vaccines, ofmonoclonal antibodies or viral vectors (gene therapies), the use of cellular expression systems (CHO, HEK293, E. coli, yeast) is essential. However, the presence ofresidual host cell DNA (HCD - Host Cell DNA) poses a major risk to patient safety (oncogenic or infectious potential).
Our laboratory specializing in biopharmaceutical supports you in the ultra-precise quantification of this residual DNA to validate the effectiveness of your purification processes and meet the strict requirements of regulatory authorities (EMA, FDA, ICH).
Why quantify residual host cell DNA?
Regulatory agencies impose strict limits: generally less than 10 ng of residual DNA per therapeutic dose, with an ideal fragment size of less than 200 base pairs.
Laboratory analysis allows you to:
Ensure patient safety: eliminate the risk of unwanted gene integration or viral sequences.
Validate your processes (Downstream Processing): prove the effectiveness of your clearance steps (chromatography, filtration, enzymatic digestion).
Ensure regulatory compliance: provide the essential analytical documentation for your clinical phases and your MAA applications (Marketing Authorization Application).
The FILAB laboratory performs residual host cell DNA analysis
Our technical methods for analyzing residual host cell DNA
To adapt to your product matrix and sensitivity requirements, our laboratory deploys two major approaches:
| Method | Key advantages | Ideal applications |
| qPCR (real-time PCR) | High specificity, industry standard, rapid quantification. | Routine quality control, process validation. |
| dPCR / ddPCR (digital PCR) | Absolute quantification without a calibration curve, extreme tolerance to matrix inhibitors, ultra-sensitivity. | Complex clinical batches, gene therapy (viral vectors), highly concentrated matrices. |
Why choose FILAB for host cell residual DNA analysis
Entrusting your analyses to the FILAB laboratory allows you to benefit from state-of-the-art equipment without investing in heavy in-house development.
Compliance with international guidelines: our analyses align with the requirements of the European (Ph. Eur.) and American (USP) pharmacopoeias, as well as the ICH Q6B guidelines.
Expert scientists: a team of PhD researchers and engineers specialized in molecular biology and biopharmaceutical method validation.
Traceability and data integrity: complete, detailed, and structured analytical reports ready to be directly integrated into your CTD registration files.
Flexible volumes: from one-off testing during the R&D phase to monitoring pre-clinical and clinical production batches.
Our services dedicated to biopharmaceutical product analysis
Identity and structure of biomolecules: primary sequence (peptide mapping), de novo sequencing
Secondary and tertiary structure analysis: thermal stability, circular dichroism (CD), UV/visible profiles and analysis by FTIR
Analysis and localization of disulfide bridges
Our FAQ
To get a quote, you can contact our teams via our contact form, by phone, or by email.
All you need to do is send us your requirements (material type, desired analysis, any applicable standard, urgency, number of samples, etc.). We will then send you a tailored technical and pricing proposal within 24-48 hours.
Lead times vary depending on the nature of the analysis and the complexity of the expert assessment project.
However, FILAB is committed to providing fast turnaround times adapted to your constraints and industrial urgencies.
Host cell residual DNA (Host Cell DNA or HCD) refers to DNA fragments originating from the cell system (e.g., CHO cells, HEK293, E. coli) used to produce a biotherapy (protein, vaccine, viral vector). Although these cells are removed during purification steps, traces of DNA may remain in the final product.
Regulatory authorities (EMA, FDA, WHO) consider residual DNA to be a risky impurity. If injected into the patient in excessive amounts or in the form of overly long fragments, this DNA presents theoretical risks of oncogenicity (activation of cancer-related genes) and infectivity (introduction of viral genomes). Its quantification is therefore mandatory to ensure batch safety.
According to WHO guidelines and the United States Pharmacopeia (USP <1132>), the standard limit is less than 10 ng of residual DNA per therapeutic dose. In addition, health agencies recommend reducing DNA fragment size to below 200 base pairs (bp) to minimize any biological risk.
